Evidence map›Paper›PMID 39738653›Full record

ArticleNature cell biology2025

TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling.

Wei-Ting Lu, Lykourgos-Panagiotis Zalmas, Chris Bailey, James R M Black, Carlos Martinez-Ruiz, Oriol Pich, Francisco Gimeno-Valiente, Ieva Usaite, Alastair Magness, Kerstin Thol and 29 more

Abstract read
In one paragraph

Article in Nature cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Targeting the Hippo pathway in cancer.Nature reviews. Drug discovery · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Wei-Ting LuThe Francis Crick Institute, London, UK. wei-ting.lu@crick.ac.uk.ORCID 0000-0002-1405-4806
Lykourgos-Panagiotis ZalmasThe Francis Crick Institute, London, UK.
Chris Bailey *The Francis Crick Institute, London, UK.ORCID 0000-0002-1602-8396
James R M Black *The Francis Crick Institute, London, UK.ORCID 0000-0001-5598-7752
Carlos Martinez-Ruiz *CRUK Lung Cancer Centre of Excellence, London, UK.
Oriol Pich *The Francis Crick Institute, London, UK.ORCID 0000-0002-1956-1882
Francisco Gimeno-ValienteCRUK Lung Cancer Centre of Excellence, London, UK.
Ieva UsaiteThe Francis Crick Institute, London, UK.
Alastair MagnessThe Francis Crick Institute, London, UK.ORCID 0000-0001-9876-3863
Kerstin TholCRUK Lung Cancer Centre of Excellence, London, UK.
Thomas A WebberThe Francis Crick Institute, London, UK.
Ming JiangThe Francis Crick Institute, London, UK.ORCID 0009-0004-1794-366X
Rebecca E SaundersThe Francis Crick Institute, London, UK.
Yun-Hsin LiuCRUK Lung Cancer Centre of Excellence, London, UK.
Dhruva BiswasThe Francis Crick Institute, London, UK.
Esther O IgeThe Francis Crick Institute, London, UK.ORCID 0009-0006-9227-8799
Birgit AerneThe Francis Crick Institute, London, UK.
Eva GrönroosThe Francis Crick Institute, London, UK.ORCID 0000-0001-8303-5409
Subramanian VenkatesanCRUK Lung Cancer Centre of Excellence, London, UK.ORCID 0000-0001-6454-8508
Georgia StavrouCRUK Lung Cancer Centre of Excellence, London, UK.ORCID 0000-0002-8427-5233
Takahiro KarasakiThe Francis Crick Institute, London, UK.
Maise Al BakirThe Francis Crick Institute, London, UK.
Matthew RenshawThe Francis Crick Institute, London, UK.ORCID 0000-0001-5238-9191
Hang XuThe Francis Crick Institute, London, UK.ORCID 0000-0002-5847-655X
Deborah Schneider-LuftmanThe Francis Crick Institute, London, UK.ORCID 0000-0001-5821-2135
Natasha SharmaCRUK Lung Cancer Centre of Excellence, London, UK.
Laura ToviniBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-4548-2811
TRACERx Consortium
Mariam Jamal-HanjaniThe Francis Crick Institute, London, UK.
Sarah E McClellandBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-9987-4511
Kevin LitchfieldCRUK Lung Cancer Centre of Excellence, London, UK.
Nicolai J BirkbakDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-1613-9587
Michael HowellThe Francis Crick Institute, London, UK.ORCID 0000-0003-0912-0079
Nicolas TaponThe Francis Crick Institute, London, UK.ORCID 0000-0001-5267-6510
Kasper FuggerUniversity College London Cancer Institute, London, UK.ORCID 0000-0001-9811-3983
Nicholas McGranahanCRUK Lung Cancer Centre of Excellence, London, UK.
Jiri BartekDanish Cancer Society Research Centre, Copenhagen, Denmark. jb@cancer.dk.ORCID 0000-0003-2013-7525
Nnennaya KanuCRUK Lung Cancer Centre of Excellence, London, UK. n.kanu@ucl.ac.uk.ORCID 0000-0001-7232-1952
Charles SwantonThe Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.ORCID 0000-0002-4299-3018

Funding

Aarhus Universitets Forskningsfond (Aarhus University Research Foundation) AUFF-E-2018-7-14Breast Cancer Research Foundation (BCRF) BCRF-22-157Breast Cancer Research Foundation (BCRF) BCRF 23-157Cancer Research UK (CRUK) C11496/A17786Cancer Research UK (CRUK) C11496/A30025Cancer Research UK (CRUK) C416/A21999Cancer Research UK (CRUK) C69256/A30194Cancer Research UK (CRUK) EDDPMA-Nov21/100034EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 835297EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) PROTEUSKr& #x00E6;ftens Bek& #x00E6;mpelse (Danish Cancer Society) R322-A17482Lundbeckfonden (Lundbeck Foundation) R272-2017-4040Novo Nordisk Fonden (Novo Nordisk Foundation) ID16584Novo Nordisk Fonden (Novo Nordisk Foundation) NNF20OC0060590Novo Nordisk Fonden (Novo Nordisk Foundation) NNF21OC0071483Novo Nordisk Fonden (Novo Nordisk Foundation) NNF23OC0085954RCUK | Medical Research Council (MRC) MR/V033077/1Rosetrees Trust M630Royal Society RP/EA/180007 & RF\ERE\231118Royal Society RSRP\R\210001Wellcome Trust CC2041Wellcome Trust (Wellcome) 211179/Z/18/Z
6 · The paper itself

Abstract

Chromosomal instability (CIN) is common in solid tumours and fuels evolutionary adaptation and poor prognosis by increasing intratumour heterogeneity. Systematic characterization of driver events in the TRACERx non-small-cell lung cancer (NSCLC) cohort identified that genetic alterations in six genes, including FAT1, result in homologous recombination (HR) repair deficiencies and CIN. Using orthogonal genetic and experimental approaches, we demonstrate that FAT1 alterations are positively selected before genome doubling and associated with HR deficiency. FAT1 ablation causes persistent replication stress, an elevated mitotic failure rate, nuclear deformation and elevated structural CIN, including chromosome translocations and radial chromosomes. FAT1 loss contributes to whole-genome doubling (a form of numerical CIN) through the dysregulation of YAP1. Co-depletion of YAP1 partially rescues numerical CIN caused by FAT1 loss but does not relieve HR deficiencies, nor structural CIN. Importantly, overexpression of constitutively active YAP1

Indexed as

CadherinsChromosomal InstabilityHippo Signaling PathwayCarcinoma, Non-Small-Cell LungCell Line, TumorGenome-Wide Association StudyHomologous RecombinationHumansLung NeoplasmsMitosisRNA, Small InterferingTranslocation, GeneticYAP-Signaling ProteinsCadherinsFAT1 protein, humanRNA, Small InterferingYAP-Signaling Proteins

Identifiers

PMID39738653
PMCPMC11735399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.